Ziel
Objective--The project aims to develop an anti HPA-1a immunoglobulin (IgG), Tromplate® that can prevent post delivery immunisation of the mother against the Human Platelet Antigen-1a (HPA-1a). This prophylactic treatment will prevent Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) in the fetus/newborn in subsequent pregnancies.
FNAIT--FNAIT is a rare but potentially serious condition which affects about 4,000 fetuses and newborns a year in EU-27 and which may result in severe bleeding, intracranial hemorrhage, fetal death or lifelong disability. FNAIT may develop when the mother and the fetus have different platelet surface antigens, most commonly HPA-1a. Transferral of HPA-1a antigen from the fetus may cause immunisation of the mother and the anti-HPA-1a antibodies she develops may in turn destroy the platelets of subsequent HPA-1a positive fetuses/newborns and cause FNAIT. Today, no good treatment of FNAIT exists.
Rationale--Previously, it was believed that the pregnant woman develops antibodies early in the first pregnancy with the implication that FNAIT could not be prevented. However, a study conducted by the applicants of more than 100,000 pregnancies revealed that HPA-1a antibody formation most often takes place in association with or after delivery. Therefore, anti-HPA-1a IgG given to the mother shortly after birth should prevent her immune system from generating harmful anti-HPA-1a antibodies. This concept is analogous to the use of anti(D) for Rhesus D prophylaxis.
Activities--The project elements: manufacturing of Tromplate® using the process for producing anti(D); screening for HPA-1a negative and pregnant women and clinical Phase II/III studies investigating the efficacy and safety of Tromplate®.
Relevance to the work program−The prophylactic Tromplate® treatment has obtained orphan drug status in Europe. FNAIT represents a significant health care expense for the society and a great burden for the affected children and their families.
Wissenschaftliches Gebiet
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
FP7-HEALTH-2012-INNOVATION-1
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
CP-FP - Small or medium-scale focused research projectKoordinator
9019 TROMSO
Norwegen
Auf der Karte ansehen
Beteiligte (11)
9220 Aalborg
Auf der Karte ansehen
Beteiligung beendet
63303 DREIEICH
Auf der Karte ansehen
68167 Mannheim
Auf der Karte ansehen
104 22 Stockholm
Auf der Karte ansehen
2750 BALLERUP
Auf der Karte ansehen
22100 Lund
Auf der Karte ansehen
0450 Oslo
Auf der Karte ansehen
9019 Tromso
Auf der Karte ansehen
9019 Tromso
Auf der Karte ansehen
291 89 Kristianstad
Auf der Karte ansehen
80686 Munchen
Auf der Karte ansehen